subscribeSubscribe
MSN`s Generic Lisdexamfetamine Dimesylate Receives Approval in the U.S.

MSN`s Generic Lisdexamfetamine Dimesylate Receives Approval in the U.S.
FDA
02 Feb 2024
Share Share
Takeda treads water despite loss of exclusivity on Vyvanse

Takeda treads water despite loss of exclusivity on Vyvanse
FIERCE PHARMA
01 Feb 2024
Share Share
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate

Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
BUSINESSWIRE
06 Sep 2023
Share Share
Mallinckrodt Receives FDA Approval for Lisdexamfetamine Dimesylate to ADHD

Mallinckrodt Receives FDA Approval for Lisdexamfetamine Dimesylate to ADHD
PR NEWSWIRE
31 Aug 2023
Share Share
Amid shortage, FDA clears several generics of Takeda`s Vyvanse

Amid shortage, FDA clears several generics of Takeda`s Vyvanse
Zoey Becker FIERCE PHARMA
31 Aug 2023
Share Share
Takeda focuses on Qdenga as it braces for Vyvanse generics

Takeda focuses on Qdenga as it braces for Vyvanse generics
Fraiser Kansteiner FIERCE PHARMA
27 Jul 2023
Share Share
As Adderall shortages persist, Takeda`s rival Vyvanse is now in short supply

As Adderall shortages persist, Takeda`s rival Vyvanse is now in short supply
Eric Sagonowsky FIERCE PHARMA
22 Jun 2023
Share Share
Sun`s Generic Lisdexamfetamine Dimesylate Receives Approval in the U.S.

Sun`s Generic Lisdexamfetamine Dimesylate Receives Approval in the U.S.
FDA
14 Jun 2023
Share Share
Ascent`s Generic Lisdexamfetamine Dimesylate Receives Receives Approval in the U.S.

Ascent`s Generic Lisdexamfetamine Dimesylate Receives Receives Approval in the U.S.
FDA
30 May 2023
Share Share
Takeda expects patent expirations to weigh on earnings

Takeda expects patent expirations to weigh on earnings
Fraiser Kansteiner FIERCE PHARMA
13 May 2023
Share Share